| Summary: | Nagla Ahmed El-Nabarawy,1 Mahmoud Hassan Teaima,2 Doaa Ahmed Helal3 1National Egyptian Center of Environmental & Toxicological Research (NECTR), Faculty of Medicine, Cairo University, Cairo, Egypt; 2Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Cairo, Egypt; 3Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Fayoum University, Elfayoum, EgyptCorrespondence: Nagla Ahmed El-NabarawyNational Egyptian Center of Environmental & Toxicological Research (NECTR), Faculty of Medicine, Cairo University, Kasr A Ainy Street, Cairo 11562, EgyptEmail n.a.nabarawy@gmail.comObjective: To develop and evaluate zolmitriptan spanlastics (Zol SLs) as a brain-targeted antimigraine delivery system. Spanlastics (SLs) prepared using span 60: tween 80 (70:30%, respectively) gave the highest percentage of entrapment efficiency (EE%).Materials and methods: A total of 60 adult male Wistar albino rats were divided into six groups (n=10 rats/group). Group 1 (Control) comprised rats serving as a negative control. Group 2 was treated with glyceryl trinitrate (NTG) and served as the positive control. Groups 3 (NTG+Zol com), Group 4 (NTG+Zol sol) and Group 5 (NTG+Zol SLs) received commercial zolmitriptan orally, zolmitriptan solution intranasally and Zol SLs F5 intranasally, respectively, 30 min before NTG. Group 6 (Zol SLs) comprised normal rats that received only Zol SLs intranasally.Results: We found decreased Tmax, increased Cmax, AUC0–6, AUC0–∞ and ameliorated behaviour in rats (head scratching) treated with intranasal SLs compared to oral commercial zolmitriptan.Conclusion: Our study substantiates the enhanced efficacy of Zol SLs in brain targeting for migraine treatment.Keywords: zolmitriptan, Zol, intranasal delivery, brain targeting, spanlastics, SLs, pharmacokinetics, pharmacodynamics, migraine
|
|---|
